Author: "Ruiz-Camps, Isabel" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Ruiz-Camps, Isabel"' showing total 307 results

Start Over Author "Ruiz-Camps, Isabel"

307 results on '"Ruiz-Camps, Isabel"'

51. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

Author: Tur, Carmen, primary, Dubessy, Anne-Laure, additional, Otero-Romero, Susana, additional, Amato, Maria Pia, additional, Derfuss, Tobias, additional, Di Pauli, Franziska, additional, Iacobaeus, Ellen, additional, Mycko, Marcin, additional, Abboud, Hesham, additional, Achiron, Anat, additional, Bellinvia, Angelo, additional, Boyko, Alexey, additional, Casanova, Jean-Laurent, additional, Clifford, David, additional, Dobson, Ruth, additional, Farez, Mauricio F, additional, Filippi, Massimo, additional, Fitzgerald, Kathryn C, additional, Fonderico, Mattia, additional, Gouider, Riadh, additional, Hacohen, Yael, additional, Hellwig, Kerstin, additional, Hemmer, Bernhard, additional, Kappos, Ludwig, additional, Ladeira, Filipa, additional, Lebrun-Frénay, Christine, additional, Louapre, Céline, additional, Magyari, Melinda, additional, Mehling, Matthias, additional, Oreja-Guevara, Celia, additional, Pandit, Lekha, additional, Papeix, Caroline, additional, Piehl, Fredrik, additional, Portaccio, Emilio, additional, Ruiz-Camps, Isabel, additional, Selmaj, Krzysztof, additional, Simpson-Yap, Steve, additional, Siva, Aksel, additional, Sorensen, Per Soelberg, additional, Sormani, Maria Pia, additional, Trojano, Maria, additional, Vaknin-Dembinsky, Adi, additional, Vukusic, Sandra, additional, Weinshenker, Brian, additional, Wiendl, Heinz, additional, Winkelmann, Alexander, additional, Zuluaga Rodas, María Isabel, additional, Tintoré, Mar, additional, and Stankoff, Bruno, additional
Published: 2022
Full Text: View/download PDF

52. Tratamiento combinado de la aspergilosis invasora. ¿Una oportunidad para micafungina?

Author: Ruiz-Camps, Isabel
Published: 2011
Full Text: View/download PDF

53. Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011

Author: Aguado, José María, Ruiz-Camps, Isabel, Muñoz, Patricia, Mensa, José, Almirante, Benito, Vázquez, Lourdes, Rovira, Montserrat, Martín-Dávila, Pilar, Moreno, Asunción, Álvarez-Lerma, Francisco, León, Cristóbal, Madero, Luis, Ruiz-Contreras, Jesús, Fortún, Jesús, and Cuenca-Estrella, Manuel
Published: 2011
Full Text: View/download PDF

54. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

Author: Pinato, David J, primary, Tabernero, Josep, additional, Bower, Mark, additional, Scotti, Lorenza, additional, Patel, Meera, additional, Colomba, Emeline, additional, Dolly, Saoirse, additional, Loizidou, Angela, additional, Chester, John, additional, Mukherjee, Uma, additional, Zambelli, Alberto, additional, Dalla Pria, Alessia, additional, Aguilar-Company, Juan, additional, Ottaviani, Diego, additional, Chowdhury, Amani, additional, Merry, Eve, additional, Salazar, Ramon, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Lambertini, Matteo, additional, Tagliamento, Marco, additional, Pous, Anna, additional, Sita-Lumsden, Ailsa, additional, Srikandarajah, Krishnie, additional, Colomba, Johann, additional, Pommeret, Fanny, additional, Seguí, Elia, additional, Generali, Daniele, additional, Grisanti, Salvatore, additional, Pedrazzoli, Paolo, additional, Rizzo, Gianpiero, additional, Libertini, Michela, additional, Moss, Charlotte, additional, Evans, Joanne S, additional, Russell, Beth, additional, Harbeck, Nadia, additional, Vincenzi, Bruno, additional, Biello, Federica, additional, Bertulli, Rossella, additional, Liñan, Raquel, additional, Rossi, Sabrina, additional, Carmona-García, Maria Carmen, additional, Tondini, Carlo, additional, Fox, Laura, additional, Baggi, Alice, additional, Fotia, Vittoria, additional, Parisi, Alessandro, additional, Porzio, Giampero, additional, Saponara, Maristella, additional, Cruz, Claudia Andrea, additional, García-Illescas, David, additional, Felip, Eudald, additional, Roqué Lloveras, Ariadna, additional, Sharkey, Rachel, additional, Roldán, Elisa, additional, Reyes, Roxana, additional, Earnshaw, Irina, additional, Ferrante, Daniela, additional, Marco-Hernández, Javier, additional, Ruiz-Camps, Isabel, additional, Gaidano, Gianluca, additional, Patriarca, Andrea, additional, Bruna, Riccardo, additional, Sureda, Anna, additional, Martinez-Vila, Clara, additional, Sanchez de Torre, Ana, additional, Cantini, Luca, additional, Filetti, Marco, additional, Rimassa, Lorenza, additional, Chiudinelli, Lorenzo, additional, Franchi, Michela, additional, Krengli, Marco, additional, Santoro, Armando, additional, Prat, Aleix, additional, Van Hemelrijck, Mieke, additional, Diamantis, Nikolaos, additional, Newsom-Davis, Thomas, additional, Gennari, Alessandra, additional, Cortellini, Alessio, additional, Swallow, Judith, additional, Chung, Chris, additional, Dettorre, Gino, additional, Chopra, Neha, additional, Lee, Alvin JX, additional, Sng, Christopher CT, additional, Wong, Yien Ning Sophia, additional, Galazi, Myria, additional, Benafif, Sarah, additional, Dileo, Palma, additional, Patel, Grisma, additional, Wu, Anjui, additional, Sinclair, Alasdair, additional, Soosaipillai, Gehan, additional, Jones, Eleanor, additional, Jackson, Amanda, additional, Piccart, Martine, additional, Colomba-Blameble, Emeline, additional, Cruz, Claudia A, additional, Segui, Elia, additional, Garcia Illescas, David, additional, Mirallas, Oriol, additional, Carbó, Anna, additional, Garcia, Isabel, additional, Wuerstlein, Rachel, additional, Mesia, Ricard, additional, Maluquer, Clara, additional, D'Avanzo, Francesca, additional, Tonini, Giuseppe, additional, Provenzano, Salvatore, additional, Tovazzi, Valeria, additional, Ficorella, Corrado, additional, Queirolo, Paola, additional, Giusti, Raffaele, additional, Mazzoni, Francesca, additional, Zoratto, Federica, additional, Tucci, Marco, additional, Berardi, Rossana, additional, Guida, Annalisa, additional, Bracarda, Sergio, additional, and Iglesias, Maria, additional
Published: 2021
Full Text: View/download PDF

55. Recent concepts in fungal involvement in skin and soft tissue infections

Author: Peghin, Maddalena, primary and Ruiz-Camps, Isabel, additional
Published: 2021
Full Text: View/download PDF

56. Pneumocystis jirovecii genetic diversity in a Spanish tertiary hospital

Author: Goterris, Lidia, primary, Pasic, Lana, additional, Guerrero Murillo, Mercedes, additional, Kan, Alex, additional, Anton, Andres, additional, Aguilar Company, Juan, additional, Ruiz-Camps, Isabel, additional, Meyer, Wieland, additional, and Martin-Gomez, María Teresa, additional
Published: 2021
Full Text: View/download PDF

57. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

Author: Piñana, José Luis, primary, Vázquez, Lourdes, additional, Martino, Rodrigo, additional, de la Cámara, Rafael, additional, Sureda, Anna, additional, Rodríguez-Veiga, Rebeca, additional, Garrido, Ana, additional, Sierra, Jorge, additional, Ribera, José-María, additional, Torrent, Anna, additional, Mateos, María Victoria, additional, de la Rubia, Javier, additional, Tormo, Mar, additional, Díez-Campelo, María, additional, García-Gutiérrez, Valentín, additional, Álvarez-Larrán, Alberto, additional, Sancho, Juan-Manuel, additional, MartínGarcía-Sancho, Alejandro, additional, Yañez, Lucrecia, additional, Pérez Simón, José Antonio, additional, Barba, Pere, additional, Abrisqueta, Pau, additional, Álvarez-Twose, Iván, additional, Bonanad, Santiago, additional, Lecumberri, Ramón, additional, Ruiz-Camps, Isabel, additional, Navarro, David, additional, Hernández-Rivas, José-Ángel, additional, Cedillo, Ángel, additional, García-Sanz, Ramón, additional, and Bosch, Francesc, additional
Published: 2021
Full Text: View/download PDF

58. Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study

Author: Pinato, David J., Scotti, Lorenza, Gennari, Alessandra, Colomba-Blameble, Emeline, Dolly, Saoirse, Loizidou, Angela, Chester, John, Mukherjee, Uma, Zambelli, Alberto, Aguilar-Company, Juan, Bower, Mark, Galazi, Myria, Salazar, Ramon, Bertuzzi, Alexia, Brunet, Joan, Mesia, Ricard, Sita-Lumsden, Ailsa, Colomba, Johann, Pommeret, Fanny, Seguí, Elia, Biello, Federica, Generali, Daniele, Grisanti, Salvatore, Rizzo, Gianpiero, Libertini, Michela, Moss, Charlotte, Evans, Joanne S., Russell, Beth, Wuerstlein, Rachel, Vincenzi, Bruno, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Marrari, Andrea, Carmona-García, M. Carmen, Sng, Christopher CT., Tondini, Carlo, Mirallas, Oriol, Tovazzi, Valeria, Fotia, Vittoria, Cruz, Claudia Andrea, Saoudi-Gonzalez, Nadia, Felip, Eudald, Roqué Lloveras, Ariadna, Lee, Alvin J.X., Newsom-Davis, Thomas, Sharkey, Rachel, Chung, Chris, García-Illescas, David, Reyes, Roxana, Sophia Wong, Yien Ning, Ferrante, Daniela, Marco-Hernández, Javier, Ruiz-Camps, Isabel, Gaidano, Gianluca, Patriarca, Andrea, Sureda, Anna, Martinez-Vila, Clara, Sanchez de Torre, Ana, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Krengli, Marco, Santoro, Armando, Prat, Aleix, Tabernero, Josep, Van Hemelrijck, Mieke, Diamantis, Nikolaos, and Cortellini, Alessio
Subjects: Europe, SARS-CoV-2, COVID-19, cancer, UK, Mortality, Original Research
Abstract: Background Despite high contagiousness and rapid spread, SARS-CoV-2 has led to heterogeneous outcomes across affected nations. Within Europe, the United Kingdom (UK) is the most severely affected country, with a death toll in excess of 100.000 as of January 2021. We aimed to compare the national impact of COVID-19 on the risk of death in UK cancer patients versus those in continental Europe (EU). Methods We performed a retrospective analysis of the OnCovid study database, a European registry of cancer patients consecutively diagnosed with COVID-19 in 27 centres from February 27 to September 10, 2020. We analysed case fatality rates and risk of death at 30 days and 6 months stratified by region of origin (UK versus EU). We compared patient characteristics at baseline, including oncological and COVID-19 specific therapy across UK and EU cohorts and evaluated the association of these factors with the risk adverse outcome in multivariable Cox regression models. Findings Compared to EU (n=924), UK patients (n=468) were characterised by higher case fatality rates (40.38% versus 26.5%, p
Published: 2021

59. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study

Author: Pinato, David J., primary, Scotti, Lorenza, additional, Gennari, Alessandra, additional, Colomba-Blameble, Emeline, additional, Dolly, Saoirse, additional, Loizidou, Angela, additional, Chester, John, additional, Mukherjee, Uma, additional, Zambelli, Alberto, additional, Aguilar-Company, Juan, additional, Bower, Mark, additional, Galazi, Myria, additional, Salazar, Ramon, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Mesia, Ricard, additional, Sita-Lumsden, Ailsa, additional, Colomba, Johann, additional, Pommeret, Fanny, additional, Seguí, Elia, additional, Biello, Federica, additional, Generali, Daniele, additional, Grisanti, Salvatore, additional, Rizzo, Gianpiero, additional, Libertini, Michela, additional, Moss, Charlotte, additional, Evans, Joanne S., additional, Russell, Beth, additional, Wuerstlein, Rachel, additional, Vincenzi, Bruno, additional, Bertulli, Rossella, additional, Ottaviani, Diego, additional, Liñan, Raquel, additional, Marrari, Andrea, additional, Carmona-García, M.C., additional, Sng, Christopher. C.T., additional, Tondini, Carlo, additional, Mirallas, Oriol, additional, Tovazzi, Valeria, additional, Fotia, Vittoria, additional, Cruz, Claudia A., additional, Saoudi-Gonzalez, Nadia, additional, Felip, Eudald, additional, R. Lloveras, Ariadna, additional, Lee, Alvin. J.X., additional, Newsom-Davis, Thomas, additional, Sharkey, Rachel, additional, Chung, Chris, additional, García-Illescas, David, additional, Reyes, Roxana, additional, Sophia Wong, Yien N., additional, Ferrante, Daniela, additional, Marco-Hernández, Javier, additional, Ruiz-Camps, Isabel, additional, Gaidano, Gianluca, additional, Patriarca, Andrea, additional, Sureda, Anna, additional, Martinez-Vila, Clara, additional, Sanchez de Torre, Ana, additional, Rimassa, Lorenza, additional, Chiudinelli, Lorenzo, additional, Franchi, Michela, additional, Krengli, Marco, additional, Santoro, Armando, additional, Prat, Aleix, additional, Tabernero, Josep, additional, V. Hemelrijck, Mieke, additional, Diamantis, Nikolaos, additional, and Cortellini, Alessio, additional
Published: 2021
Full Text: View/download PDF

60. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

Author: Dettorre, Gino M., Dolly, Saoirse, Loizidou, Angela, Chester, John, Jackson, Amanda, Mukherjee, Uma, Zambelli, Alberto, Aguilar Company, Juan, Bower, Mark, Sng, Christopher C. T., Salazar Soler, Ramón, Bertuzzi, Alexia, Brunet, Joan, Mesia, Ricard, Sita-Lumsden, Ailsa, Seguí, Elia, Biello, Federica, Generali, Daniele, Grisanti, Salvatore, Seeva, Pavetha, Rizzo, Gianpiero, Libertini, Michela, Maconi, Antonio, Moss, Charlotte, Russell, Beth, Harbeck, Nadia, Vincenzi, Bruno, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Marrari, Andrea, Carmona García, M. Carmen, Chopra, Neha, Tondini, Carlo Alberto, Mirallas, Oriol, Tovazzi, Valeria, Fotia, Vittoria, Cruz, Claudia Andrea, Saoudi González, Nadia, Felip, Eudald, Roqué, Ariadna, Lee, Alvin J. X., Newsom-Davis, Tom, García Illescas, David, Reyes, Roxana, Wong, Yien Ning Sophia, Ferrante, Daniela, Scotti, Lorenza, Marco Hernández, Javier, Ruiz Camps, Isabel, Patriarca, Andrea, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Santoro, Armando, Prat Aparicio, Aleix, Gennari, Alessandra, Van Hemelrijck, Mieke, Tabernero Caturla, Josep, Diamantis, Nikolaos, Pinato, David J., OnCovid study group, Dettorre, G. M., Dolly, S., Loizidou, A., Chester, J., Jackson, A., Mukherjee, U., Zambelli, A., Aguilar-Company, J., Bower, M., Sng, C. C. T., Salazar, R., Bertuzzi, A., Brunet, J., Mesia, R., Sita-Lumsden, A., Segui, E., Biello, F., Generali, D., Grisanti, S., Seeva, P., Rizzo, G., Libertini, M., Maconi, A., Moss, C., Russell, B., Harbeck, N., Vincenzi, B., Bertulli, R., Ottaviani, D., Linan, R., Marrari, A., Carmen Carmona-Garcia, M., Chopra, N., Tondini, C. A., Mirallas, O., Tovazzi, V., Fotia, V., Cruz, C. A., Saoudi-Gonzalez, N., Felip, E., Roque, A., Lee, A. J. X., Newsom-Davis, T., Garcia-Illescas, D., Reyes, R., Wong, Y. N. S., Ferrante, D., Scotti, L., Marco-Hernandez, J., Ruiz-Camps, I., Patriarca, A., Rimassa, L., Chiudinelli, L., Franchi, M., Santoro, A., Prat, A., Gennari, A., Van Hemelrijck, M., Tabernero, J., Diamantis, N., Pinato, D. J., Wellcome Trust, Institut Català de la Salut, [Dettorre GM] Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. [Dolly S] Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust (GSTT), London, UK. [Loizidou A] Department of Infectious Diseases, Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. [Chester J] Medical Oncology, School of Medicine, Cardiff University, Cardiff, UK. Medical Oncology, Velindre Cancer Centre, Cardiff, UK. [Jackson A] Clinical Trials, Velindre Cancer Centre, Cardiff, UK. [Mukherjee U] Medical Oncology, Barts Health NHS Trust, London, UK. [Aguilar-Company J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Mirallas O, Saoudi-Gonzalez N, García-Illescas D] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Ruiz-Camps I] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Male, 0301 basic medicine, Oncology, Cancer Research, Comorbidity, Systemic inflammation, Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores], COVID-19 Testing, 0302 clinical medicine, Neoplasms, Immunotherapy Biomarkers, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], 80 and over, Immunology and Allergy, Medicine, Hypoalbuminemia, Young adult, Càncer, Multivariate Analysi, RC254-282, COVID-19 (Malaltia) - Complicacions, Cancer, Aged, 80 and over, OnCovid study group, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Middle Aged, Prognosis, Inflamació, Systemic Inflammatory Response Syndrome, 030220 oncology & carcinogenesis, Cohort, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation::Systemic Inflammatory Response Syndrome [DISEASES], Molecular Medicine, Female, medicine.symptom, Life Sciences & Biomedicine, Human, Adult, medicine.medical_specialty, Prognosi, Càncer - Epidemiologia, Immunology, neoplasias [ENFERMEDADES], inflammation mediator, Young Adult, 03 medical and health sciences, Internal medicine, Humans, afecciones patológicas, signos y síntomas::procesos patológicos::inflamación::síndrome de respuesta inflamatoria sistémica [ENFERMEDADES], Aged, Pharmacology, Science & Technology, business.industry, SARS-CoV-2, COVID-19, medicine.disease, inflammation, inflammation mediators, Blood Cell Count, Multivariate Analysis, Neoplasms [DISEASES], Systemic inflammatory response syndrome, 030104 developmental biology, Neoplasm, Lymphocytopenia, business, Other subheadings::Other subheadings::/complications [Other subheadings]
Abstract: Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflamació; Mediadors d'inflamació Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflamación; Mediadores de la inflamación Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflammation; Inflammation mediators Background Patients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver of severity and mortality from COVID-19, evaluating the prognostic role of commonly used inflammatory indices in SARS-CoV-2-infected patients with cancer accrued to the OnCovid study. Methods In a multicenter cohort of SARS-CoV-2-infected patients with cancer in Europe, we evaluated dynamic changes in neutrophil:lymphocyte ratio (NLR); platelet:lymphocyte ratio (PLR); Prognostic Nutritional Index (PNI), renamed the OnCovid Inflammatory Score (OIS); modified Glasgow Prognostic Score (mGPS); and Prognostic Index (PI) in relation to oncological and COVID-19 infection features, testing their prognostic potential in independent training (n=529) and validation (n=542) sets. Results We evaluated 1071 eligible patients, of which 625 (58.3%) were men, and 420 were patients with malignancy in advanced stage (39.2%), most commonly genitourinary (n=216, 20.2%). 844 (78.8%) had ≥1 comorbidity and 754 (70.4%) had ≥1 COVID-19 complication. NLR, OIS, and mGPS worsened at COVID-19 diagnosis compared with pre-COVID-19 measurement (p
Published: 2021

61. Additional file 1 of Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

Author: Muntañola, Ana, Villacampa, Guillermo, Hernández-Rivas, José Ángel, Alonso, Rosalía, Mirás, Fátima, Osorio, Santiago, Baile, Mónica, Baltasar, Patricia, Jiménez, Javier López, Hernandez-Rodriguez, Ines, Valenciano, Susana, Alfayate, Ana, Gimeno, Eva, Bárez, Abelardo, Oliveira, Ana C., Riaza, Rosalía, Romero, Pilar, Delgado, Julio, Lucrecia Yáñez, Zabalza, Amaya, Torres, Ana, Mª Isabel Gómez-Roncero, Crespo, Marta, Córdoba, Raúl, Mateos-Mazón, Juan José, Pérez, Sonia, Andreu, Rafael, Labrador, Jorge, Mª Elena Ruiz, Velasquez, César Andrés, Mª José Terol, Santiago, Raquel, Mª Jesús Vidal, Fiz Campoy García, Villalón, Lucía, Muiña, Begoña S., Soler, Joan Alfons, Seri, Cristina, Mª José Sánchez, Cuesta, Amalia, Ramos, Rafael, Sánchez-Montalvá, Adrián, Ruiz-Camps, Isabel, González, Marcos, Abrisqueta, Pau, and Bosch, Francesc
Abstract: Additional file 1: Table S1. Patient and CLL features at the time of COVID-19 infection (n = 165). Table S2. COVID-19 manifestations, management, and outcomes. Table S3. Univariate and multivariate OS analysis of baseline characteristics. Table S4. Characteristics of patients infected by SARS-CoV-2 i) treated at University Hospital Vall d’Hebron and ii) overall Spanish population. Figure S1. Levels of inflammatory parameters according to treatment with BTKi. (* indicates p
Published: 2021
Full Text: View/download PDF

62. Potencial de anidulafungina en el paciente hematológico

Author: Vázquez López, Lourdes and Ruiz Camps, Isabel
Published: 2008
Full Text: View/download PDF

63. Aspergillosis: Beyond the oncohematological patient

Author: Ruiz Camps, Isabel
Published: 2020
Full Text: View/download PDF

64. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

Author: Dettorre, Gino M, primary, Dolly, Saoirse, additional, Loizidou, Angela, additional, Chester, John, additional, Jackson, Amanda, additional, Mukherjee, Uma, additional, Zambelli, Alberto, additional, Aguilar-Company, Juan, additional, Bower, Mark, additional, Sng, Christopher C T, additional, Salazar, Ramon, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Mesia, Ricard, additional, Sita-Lumsden, Ailsa, additional, Seguí, Elia, additional, Biello, Federica, additional, Generali, Daniele, additional, Grisanti, Salvatore, additional, Seeva, Pavetha, additional, Rizzo, Gianpiero, additional, Libertini, Michela, additional, Maconi, Antonio, additional, Moss, Charlotte, additional, Russell, Beth, additional, Harbeck, Nadia, additional, Vincenzi, Bruno, additional, Bertulli, Rossella, additional, Ottaviani, Diego, additional, Liñan, Raquel, additional, Marrari, Andrea, additional, Carmona-García, M Carmen, additional, Chopra, Neha, additional, Tondini, Carlo Alberto, additional, Mirallas, Oriol, additional, Tovazzi, Valeria, additional, Fotia, Vittoria, additional, Cruz, Claudia Andrea, additional, Saoudi-Gonzalez, Nadia, additional, Felip, Eudald, additional, Roqué, Ariadna, additional, Lee, Alvin J X, additional, Newsom-Davis, Tom, additional, García-Illescas, David, additional, Reyes, Roxana, additional, Wong, Yien Ning Sophia, additional, Ferrante, Daniela, additional, Scotti, Lorenza, additional, Marco-Hernández, Javier, additional, Ruiz-Camps, Isabel, additional, Patriarca, Andrea, additional, Rimassa, Lorenza, additional, Chiudinelli, Lorenzo, additional, Franchi, Michela, additional, Santoro, Armando, additional, Prat, Aleix, additional, Gennari, Alessandra, additional, Van Hemelrijck, Mieke, additional, Tabernero, Josep, additional, Diamantis, Nikolaos, additional, and Pinato, David J, additional
Published: 2021
Full Text: View/download PDF

65. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

Author: Muntañola, Ana, Villacampa, Guillermo, Hernández-Rivas, José Ángel, Alonso, Rosalía, Mirás, Fátima, Osorio, Santiago, Baile, Mónica, Baltasar, Patricia, López Jiménez, Javier, Hernández‑Rodríguez, Inés, Valenciano, Susana, Alfayate, Ana, Gimeno, Eva, Bárez, Abelardo, Oliveira, Ana Carla, Riaza Grau, Rosalía, Romero, Pilar, Delgado, Julio, Yáñez, Lucrecia, Zabalza, Amaya, Torres, Ana, Gómez-Roncero, María Isabel, Crespo, Marta, Córdoba, Raúl, Mateos, Juan José, Pérez, Sonia, Andreu, Rafael, Labrador, Jorge, Ruiz, María Elena, Velasquez, César Andrés, Terol, María José, Santiago, Raquel, Vidal, María Jesús, Campoy García, Fiz, Villalón, Lucía, Muiña, Begoña, Soler, Joan Alfons, Seri, Cristina, Sánchez, María José, Cuesta, Amalia, Ramos, Rafael, Sánchez‑Montalvá, Sánchez‑Montalvá, Adrán, Ruiz‑Camps, Isabel, González, Marcos, Abrisqueta, Pau, Bosch, Francesc, Abrisqueta, Pau [0000-0001-9625-7422], and Abrisqueta, Pau
Subjects: Cancer Research, 2019-20 coronavirus outbreak, medicine.medical_specialty, Leucèmia limfoide, Hematology, Coronavirus disease 2019 (COVID-19), business.industry, lcsh:RC633-647.5, Chronic lymphocytic leukemia, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, lcsh:Diseases of the blood and blood-forming organs, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, COVID-19 (Malaltia), lcsh:RC254-282, Oncology, Internal medicine, medicine, business, Letter to the Editor
Abstract: Spain has been one the most affected countries by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) pandemic [1, 2]. Patients with chronic lymphocytic leukemia (CLL) could be at risk of more severe COVID-19 clinical forms [3] since they often carry immune perturbations aggravated by treatments used for the disease itself [4]. Two major series on patients with COVID-19 and CLL encompassing different countries and health systems reported heterogeneous factors related to the outcome [5, 6]. Herein, we are presenting the largest series of CLL patients with proved COVID-19 from a single country and Health system.
Published: 2020

66. Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe

Author: Pinato, David J., Lee, Alvin J.X., Biello, Federica, Seguí, Elia, Aguilar-Company, Juan, Carbó, Anna, Bruna, Riccardo, Bower, Mark, Rizzo, Gianpiero, Benafif, Sarah, Carmona, Carme, Chopra, Neha, Cruz, Claudia Andrea, D'avanzo, Francesca, Evans, Joanne S., Galazi, Myria, Garcia-Fructuoso, Isabel, Pria, Alessia D., Newsom-Davis, Thomas, Ottaviani, Diego, Patriarca, Andrea, Reyes, Roxana, Sharkey, Rachel, Sng, Christopher C.T., Wong, Yien Ning Sophia, Ferrante, Daniela, Scotti, Lorenza, Avanzi, Gian Carlo, Bellan, Mattia, Castello, Luigi Mario, Marco-Hernández, Javier, Mollà, Meritxell, Pirisi, Mario, Ruiz-Camps, Isabel, Sainaghi, Pier Paolo, Gaidano, Gianluca, Brunet, Joan, Tabernero, Josep, Prat, Aleix, Gennari, Alessandra, Universitat Autònoma de Barcelona, Pinato, David J., Lee, Alvin J.X., Biello, Federica, Seguí, Elia, Aguilar-Company, Juan, Carbó, Anna, Bruna, Riccardo, Bower, Mark, Rizzo, Gianpiero, Benafif, Sarah, Carmona, Carme, Chopra, Neha, Cruz, Claudia Andrea, D'avanzo, Francesca, Evans, Joanne S., Galazi, Myria, Garcia-Fructuoso, Isabel, Pria, Alessia D., Newsom-Davis, Thomas, Ottaviani, Diego, Patriarca, Andrea, Reyes, Roxana, Sharkey, Rachel, Sng, Christopher C.T., Wong, Yien Ning Sophia, Ferrante, Daniela, Scotti, Lorenza, Avanzi, Gian Carlo, Bellan, Mattia, Castello, Luigi Mario, Marco-Hernández, Javier, Mollà, Meritxell, Pirisi, Mario, Ruiz-Camps, Isabel, Sainaghi, Pier Paolo, Gaidano, Gianluca, Brunet, Joan, Tabernero, Josep, Prat, Aleix, Gennari, Alessandra, and Universitat Autònoma de Barcelona
Abstract: Funding: D.J.P. is supported by grant funding from the Wellcome Trust Strategic Fund (PS3416) and acknowledges grant support by the Cancer Treatment and Research Trust (CTRT) as well as infrastructural support by the Cancer Research UK Imperial Centre. GG is supported by the AIRC 5 × 1000 Grant, No. 21198, Associazione Italiana per la Ricerca sul Cancro Foundation, Milan, Italy. A.G. is supported by the AIRC IG grant, No. 14230, Associazione Italiana per la Ricerca sul Cancro Foundation, Milan, Italy. A.G., G.G., G.C.A., L.M.C., M.B., P.P.S., M.P. from the University of Piemonte Orientale acknowledge support from the UPO Aging Project., We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. We identified 204 cancer patients from eight centers in the United Kingdom, Italy, and Spain aged > 18 (mean = 69) and diagnosed with COVID-19 between February 26th and April 1st, 2020. A total of 127 (62%) were male, 184 (91%) had a diagnosis of solid malignancy, and 103 (51%) had non-metastatic disease. A total of 161 (79%) had > 1 co-morbidity. A total of 141 (69%) patients had > 1 COVID-19 complication. A total of 36 (19%) were escalated to high-dependency or intensive care. A total of 59 (29%) died, 53 (26%) were discharged, and 92 (45%) were in-hospital survivors. Mortality was higher in patients aged > 65 (36% versus 16%), in those with > 2 co-morbidities (40% versus 18%) and developing > 1 complication from COVID-19 (38% versus 4%, p = 0.004). Multi-variable analyses confirmed age > 65 and > 2 co-morbidities to predict for patient mortality independent of tumor stage, active malignancy, or anticancer therapy. During the early outbreak of SARS-CoV-2 infection in Europe co-morbid burden and advancing age predicted for adverse disease course in cancer patients. The ongoing OnCovid study will allow us to compare risks and outcomes in cancer patients between the initial and later stages of the COVID-19 pandemic.
Published: 2020

67. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa

Author: Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), Red Española de Investigación en Patología Infecciosa, European Commission, Promex Stiftung Fur Die Forschung, Gilead Sciences, MSD, Astellas Pharma, Novartis, Pfizer, Gudiol, Carlota, Albasanz-Puig, Adaia, Laporte-Amargós, Júlia, Pallarès, Natalia, Mussetti, Alberto, Ruiz-Camps, Isabel, Puerta-Alcalde, Pedro, Abdala, Edson, Oltolini, Chiara, Akova, Murat, Montejo, Miguel, Mikulska, Malgorzata, Martín-Dávila, Pilar, Herrera, Fabián, Gasch, Oriol, Drgona, Lubos, Paz Morales, Hugo Manuel, Brunel, Anne-Sophie, García, Estefanía, Isler, Burcu, Kern, Winfried, Morales, Isabel, Maestro-de la Calle, Guillermo, Montero, Milagros, Kanj, Souha S., Sipahi, Oguz Resat, Calik, Sebnem, Márquez-Gómez, Ignacio, Marin, Jorge Iván, Gomes, Marisa Z. R., Hemmati, Philipp, Araos, Rafael, Peghin, Maddalena, Pozo, José Luis del, Yáñez, Lucrecia, Tilley, Robert, Manzur, Adriana, Novo, Andrés, Carratalà, Jordi, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), Red Española de Investigación en Patología Infecciosa, European Commission, Promex Stiftung Fur Die Forschung, Gilead Sciences, MSD, Astellas Pharma, Novartis, Pfizer, Gudiol, Carlota, Albasanz-Puig, Adaia, Laporte-Amargós, Júlia, Pallarès, Natalia, Mussetti, Alberto, Ruiz-Camps, Isabel, Puerta-Alcalde, Pedro, Abdala, Edson, Oltolini, Chiara, Akova, Murat, Montejo, Miguel, Mikulska, Malgorzata, Martín-Dávila, Pilar, Herrera, Fabián, Gasch, Oriol, Drgona, Lubos, Paz Morales, Hugo Manuel, Brunel, Anne-Sophie, García, Estefanía, Isler, Burcu, Kern, Winfried, Morales, Isabel, Maestro-de la Calle, Guillermo, Montero, Milagros, Kanj, Souha S., Sipahi, Oguz Resat, Calik, Sebnem, Márquez-Gómez, Ignacio, Marin, Jorge Iván, Gomes, Marisa Z. R., Hemmati, Philipp, Araos, Rafael, Peghin, Maddalena, Pozo, José Luis del, Yáñez, Lucrecia, Tilley, Robert, Manzur, Adriana, Novo, Andrés, and Carratalà, Jordi
Abstract: We aimed to assess the rate and predictive factors of bloodstream infection (BSI) due to multidrug-resistant (MDR) Pseudomonas aeruginosa in neutropenic cancer patients. We performed a multicenter, retrospective cohort study including oncohematological neutropenic patients with BSI due to P. aeruginosa conducted across 34 centers in 12 countries from January 2006 to May 2018. A mixed logistic regression model was used to estimate a model to predict the multidrug resistance of the causative pathogens. Of a total of 1,217 episodes of BSI due to P. aeruginosa, 309 episodes (25.4%) were caused by MDR strains. The rate of multidrug resistance increased significantly over the study period (P = 0.033). Predictors of MDR P. aeruginosa BSI were prior therapy with piperacillin-tazobactam (odds ratio [OR], 3.48; 95% confidence interval [CI], 2.29 to 5.30), prior antipseudomonal carbapenem use (OR, 2.53; 95% CI, 1.65 to 3.87), fluoroquinolone prophylaxis (OR, 2.99; 95% CI, 1.92 to 4.64), underlying hematological disease (OR, 2.09; 95% CI, 1.26 to 3.44), and the presence of a urinary catheter (OR, 2.54; 95% CI, 1.65 to 3.91), whereas older age (OR, 0.98; 95% CI, 0.97 to 0.99) was found to be protective. Our prediction model achieves good discrimination and calibration, thereby identifying neutropenic patients at higher risk of BSI due to MDR P. aeruginosa. The application of this model using a web-based calculator may be a simple strategy to identify high-risk patients who may benefit from the early administration of broad-spectrum antibiotic coverage against MDR strains according to the local susceptibility patterns, thus avoiding the use of broad-spectrum antibiotics in patients at a low risk of resistance development.
Published: 2020

68. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

Author: Abrisqueta, Pau [0000-0001-9625-7422], Muntañola, Ana, Villacampa, Guillermo, Hernández-Rivas, José Ángel, Alonso, Rosalía, Mirás, Fátima, Osorio, Santiago, Baile, Mónica, Baltasar, Patricia, López Jiménez, Javier, Hernández‑Rodríguez, Inés, Valencia, Susana, Alfayate, Ana, Gimeno, Eva, Bárez, Abelardo, Oliveira, Ana Carla, Riaza Grau, Rosalía, Romero, Pilar, Delgado, Julio, Yáñez, Lucrecia, Zabalza, Amaya, Torres, Ana, Gómez-Roncero, María Isabel, Crespo, Marta, Córdoba, Raúl, Mateos, Juan José, Pérez, Sonia, Andreu, Rafael, Labrador, Jorge, Ruiz, María Elena, Velasquez, César Andrés, Terol, María José, Santiago, Raquel, Vidal, María Jesús, Campoy García, Fiz, Villalón, Lucía, Muiña, Begoña, Soler, Joan Alfons, Seri, Cristina, Sánchez, María José, Cuesta, Amalia, Ramos, Rafael, Sánchez‑Montalvá, Sánchez‑Montalvá, Adrán, Ruiz‑Camps, Isabel, González, Marcos, Abrisqueta, Pau, Bosch, Francesc, Abrisqueta, Pau [0000-0001-9625-7422], Muntañola, Ana, Villacampa, Guillermo, Hernández-Rivas, José Ángel, Alonso, Rosalía, Mirás, Fátima, Osorio, Santiago, Baile, Mónica, Baltasar, Patricia, López Jiménez, Javier, Hernández‑Rodríguez, Inés, Valencia, Susana, Alfayate, Ana, Gimeno, Eva, Bárez, Abelardo, Oliveira, Ana Carla, Riaza Grau, Rosalía, Romero, Pilar, Delgado, Julio, Yáñez, Lucrecia, Zabalza, Amaya, Torres, Ana, Gómez-Roncero, María Isabel, Crespo, Marta, Córdoba, Raúl, Mateos, Juan José, Pérez, Sonia, Andreu, Rafael, Labrador, Jorge, Ruiz, María Elena, Velasquez, César Andrés, Terol, María José, Santiago, Raquel, Vidal, María Jesús, Campoy García, Fiz, Villalón, Lucía, Muiña, Begoña, Soler, Joan Alfons, Seri, Cristina, Sánchez, María José, Cuesta, Amalia, Ramos, Rafael, Sánchez‑Montalvá, Sánchez‑Montalvá, Adrán, Ruiz‑Camps, Isabel, González, Marcos, Abrisqueta, Pau, and Bosch, Francesc
Abstract: Spain has been one the most affected countries by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) pandemic [1, 2]. Patients with chronic lymphocytic leukemia (CLL) could be at risk of more severe COVID-19 clinical forms [3] since they often carry immune perturbations aggravated by treatments used for the disease itself [4]. Two major series on patients with COVID-19 and CLL encompassing different countries and health systems reported heterogeneous factors related to the outcome [5, 6]. Herein, we are presenting the largest series of CLL patients with proved COVID-19 from a single country and Health system.
Published: 2020

69. Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective

Author: Soosaipillai, Gehan, primary, Wu, Anjui, additional, Dettorre, Gino M, additional, Diamantis, Nikolaos, additional, Chester, John, additional, Moss, Charlotte, additional, Aguilar-Company, Juan, additional, Bower, Mark, additional, Sng, Christopher CT, additional, Salazar, Ramon, additional, Brunet, Joan, additional, Jones, Eleanor, additional, Mesia, Ricard, additional, Jackson, Amanda, additional, Mukherjee, Uma, additional, Sita-Lumsden, Ailsa, additional, Seguí, Elia, additional, Ottaviani, Diego, additional, Carbó, Anna, additional, Benafif, Sarah, additional, Würstlein, Rachel, additional, Carmona, Carme, additional, Chopra, Neha, additional, Cruz, Claudia Andrea, additional, Swallow, Judith, additional, Saoudi, Nadia, additional, Felip, Eudald, additional, Galazi, Myria, additional, Garcia-Fructuoso, Isabel, additional, Lee, Alvin J. X., additional, Newsom-Davis, Thomas, additional, Wong, Yien Ning Sophia, additional, Sureda, Anna, additional, Maluquer, Clara, additional, Ruiz-Camps, Isabel, additional, Cabirta, Alba, additional, Prat, Aleix, additional, Loizidou, Angela, additional, Gennari, Alessandra, additional, Ferrante, Daniela, additional, Tabernero, Josep, additional, Russell, Beth, additional, Van Hemelrijck, Mieke, additional, Dolly, Saoirse, additional, Hulbert-Williams, Nicholas J, additional, Pinato, David J, additional, Mollà, Meritxell, additional, Reyes, Roxana, additional, Marco-Hernández, Javier, additional, Bruna, Riccardo, additional, Biello, Federica, additional, Patriarca, Andrea, additional, Zambelli, Alberto, additional, Tondini, Carlo, additional, Fotia, Vittoria, additional, Chiudinelli, Lorenzo, additional, Franchi, Michela, additional, Generali, Daniele, additional, Grisanti, Salvatore, additional, Tovazzi, Valeria, additional, Bertuzzi, Alexia, additional, Marrari, Andrea, additional, Seeva, Pavetha, additional, Dileo, Palma, additional, Rizzo, Gianpiero, additional, Libertini, Michela, additional, Maconi, Antonio, additional, Betti, Marta, additional, Provenzano, Salvatore, additional, Harbeck, Nadia, additional, Vincenzi, Bruno, additional, Bertulli, Rossella, additional, Liñan, Raquel, additional, Roqué, Ariadna, additional, Mirallas, Oriol, additional, García-Illescas, David, additional, Scotti, Lorenza, additional, Dalla Pria, Alessia, additional, D’Avanzo, Francesca, additional, Martinez, Maria, additional, Evans, Joanne S, additional, Sharkey, Rachel, additional, Rimassa, Lorenza, additional, Santoro, Armando, additional, Gaidano, Gianluca, additional, and Izuzquiza, Macarena, additional
Published: 2021
Full Text: View/download PDF

70. Risk of infection associated with targeted therapies for solid organ and hematological malignancies

Author: Ruiz-Camps, Isabel, primary and Aguilar-Company, Juan, additional
Published: 2021
Full Text: View/download PDF

71. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain

Author: Cabirta, Alba, primary, Izuzquiza, Macarena, additional, Ruiz-Camps, Isabel, additional, Valcarcel, David, additional, Catala, Eva, additional, Jimenez, M Moraima, additional, Perez, Ana, additional, Martin, Lucia, additional, Rodriguez, Yva, additional, Serna, Angel, additional, Ruiz-Pace, Fiorella, additional, Dienstmann, Rodrigo, additional, Bobillo, Sabela, additional, Carpio, Cecilia, additional, Salamero, Olga, additional, Abrisqueta, Pau, additional, and Bosch, Francesc, additional
Published: 2020
Full Text: View/download PDF

72. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

Author: Pinato, David J., primary, Zambelli, Alberto, additional, Aguilar-Company, Juan, additional, Bower, Mark, additional, Sng, Christopher C.T., additional, Salazar, Ramon, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Mesia, Ricard, additional, Seguí, Elia, additional, Biello, Federica, additional, Generali, Daniele, additional, Grisanti, Salvatore, additional, Rizzo, Gianpiero, additional, Libertini, Michela, additional, Maconi, Antonio, additional, Harbeck, Nadia, additional, Vincenzi, Bruno, additional, Bertulli, Rossella, additional, Ottaviani, Diego, additional, Carbó, Anna, additional, Bruna, Riccardo, additional, Benafif, Sarah, additional, Marrari, Andrea, additional, Wuerstlein, Rachel, additional, Carmona-Garcia, M. Carmen, additional, Chopra, Neha, additional, Tondini, Carlo, additional, Mirallas, Oriol, additional, Tovazzi, Valeria, additional, Betti, Marta, additional, Provenzano, Salvatore, additional, Fotia, Vittoria, additional, Cruz, Claudia Andrea, additional, Dalla Pria, Alessia, additional, D'Avanzo, Francesca, additional, Evans, Joanne S., additional, Saoudi-Gonzalez, Nadia, additional, Felip, Eudald, additional, Galazi, Myria, additional, Garcia-Fructuoso, Isabel, additional, Lee, Alvin J.X., additional, Newsom-Davis, Thomas, additional, Patriarca, Andrea, additional, García-Illescas, David, additional, Reyes, Roxana, additional, Dileo, Palma, additional, Sharkey, Rachel, additional, Wong, Yien Ning Sophia, additional, Ferrante, Daniela, additional, Marco-Hernández, Javier, additional, Sureda, Anna, additional, Maluquer, Clara, additional, Ruiz-Camps, Isabel, additional, Gaidano, Gianluca, additional, Rimassa, Lorenza, additional, Chiudinelli, Lorenzo, additional, Izuzquiza, Macarena, additional, Cabirta, Alba, additional, Franchi, Michela, additional, Santoro, Armando, additional, Prat, Aleix, additional, Tabernero, Josep, additional, Gennari, Alessandra, additional, Avanzi, Gian Carlo, additional, Bellan, Mattia, additional, Castello, Luigi Mario, additional, Martinez, Maria, additional, Mollà, Meritxell, additional, Pirisi, Mario, additional, Scotti, Lorenza, additional, and Swallow, Judith, additional
Published: 2020
Full Text: View/download PDF

73. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

Author: Los-Arcos, Ibai, primary, Iacoboni, Gloria, additional, Aguilar-Guisado, Manuela, additional, Alsina-Manrique, Laia, additional, Díaz de Heredia, Cristina, additional, Fortuny-Guasch, Claudia, additional, García-Cadenas, Irene, additional, García-Vidal, Carolina, additional, González-Vicent, Marta, additional, Hernani, Rafael, additional, Kwon, Mi, additional, Machado, Marina, additional, Martínez-Gómez, Xavier, additional, Maldonado, Valentín Ortiz, additional, Pla, Carolina Pinto, additional, Piñana, José Luis, additional, Pomar, Virginia, additional, Reguera-Ortega, Juan Luis, additional, Salavert, Miguel, additional, Soler-Palacín, Pere, additional, Vázquez-López, Lourdes, additional, Barba, Pere, additional, and Ruiz-Camps, Isabel, additional
Published: 2020
Full Text: View/download PDF

74. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe

Author: Pinato, David J., primary, Lee, Alvin J. X., additional, Biello, Federica, additional, Seguí, Elia, additional, Aguilar-Company, Juan, additional, Carbó, Anna, additional, Bruna, Riccardo, additional, Bower, Mark, additional, Rizzo, Gianpiero, additional, Benafif, Sarah, additional, Carmona, Carme, additional, Chopra, Neha, additional, Cruz, Claudia Andrea, additional, D’Avanzo, Francesca, additional, Evans, Joanne S., additional, Galazi, Myria, additional, Garcia-Fructuoso, Isabel, additional, Dalla Pria, Alessia, additional, Newsom-Davis, Thomas, additional, Ottaviani, Diego, additional, Patriarca, Andrea, additional, Reyes, Roxana, additional, Sharkey, Rachel, additional, Sng, Christopher C. T., additional, Wong, Yien Ning Sophia, additional, Ferrante, Daniela, additional, Scotti, Lorenza, additional, Avanzi, Gian Carlo, additional, Bellan, Mattia, additional, Castello, Luigi Mario, additional, Marco-Hernández, Javier, additional, Mollà, Meritxell, additional, Pirisi, Mario, additional, Ruiz-Camps, Isabel, additional, Sainaghi, Pier Paolo, additional, Gaidano, Gianluca, additional, Brunet, Joan, additional, Tabernero, Josep, additional, Prat, Aleix, additional, and Gennari, Alessandra, additional
Published: 2020
Full Text: View/download PDF

75. Risk of infection associated with new therapies for lymphoproliferative syndromes

Author: Los-Arcos, Ibai, primary, Aguilar-Company, Juan, additional, and Ruiz-Camps, Isabel, additional
Published: 2020
Full Text: View/download PDF

76. Riesgo de infección asociada a nuevas terapias para el tratamiento de los síndromes linfoproliferativos

Author: Los-Arcos, Ibai, primary, Aguilar-Company, Juan, additional, and Ruiz-Camps, Isabel, additional
Published: 2020
Full Text: View/download PDF

77. Molecular Diagnosis of Pneumocystis jirovecii Pneumonia by Use of Oral Wash Samples in Immunocompromised Patients: Usefulness and Importance of the DNA Target

Author: Goterris, Lidia, primary, Mancebo Fernández, Miguel Angel, additional, Aguilar-Company, Juan, additional, Falcó, Vicenç, additional, Ruiz-Camps, Isabel, additional, and Martín-Gómez, M. Teresa, additional
Published: 2019
Full Text: View/download PDF

78. Pneumocystis jirovecii genetic diversity in a Spanish tertiary hospital.

Author: Goterris, Lidia, Pasic, Lana, Murillo, Mercedes Guerrero, Kan, Alex, Anton, Andres, Company, Juan Aguilar, Ruiz-Camps, Isabel, Meyer, Wieland, and Martin-Gomez, María Teresa
Abstract: Pneumocystis jirovecii is associated with non-noxious colonization or severe pneumonia in immunocompromised hosts. Epidemiological investigations have been hampered by the lack of a standardized typing scheme. Thus, only partial molecular data on Spanish P. jirovecii cases are available. Recently, a new ISHAM consensus multilocus sequence typing scheme (MLST) targeting β-TUB, mt26S, CYB , and SOD with a publicly accessible database has been launched to overcome this problem. The molecular epidemiology of P. jirovecii from immunocompromised patients either colonized (n = 50) or having pneumonia (n = 36) seen between 2014 and 2018 at a single center in Barcelona, Spain, was studied. The new ISHAM consensus MSLT scheme was used to investigate the local epidemiology and identify possible unnoticed outbreaks. Mutations in the DHPS gene, not included in the scheme but giving information about potential sulfa treatment failure, were also studied. The study assigned 32 sequence types (ST) to 72.2% pneumonia and 56% colonization cases. The most frequent STs were ST21 (18.5%), ST22 (14.8%), and ST37(14.8%). For non-unique STs, ST3, ST30 and ST31 were found only in pneumonia cases, whereas ST27 was associated exclusively to colonizations. Despite 38 patients sharing similar STs, only two were involved in a potential cross transmission event. No DHPS mutations were identified. The new consensus typing scheme was useful to ascertain the molecular epidemiology of P. jirovecii in our center revealing a high genetic diversity and the potential association of specific STs to colonization and pneumonia cases. Lay Summary A newly described MLST scheme aims at providing a standardized tool to study and compare Pneumocystis jirovecii epidemiology. A high diversity among P. jirovecii isolates from patients in Barcelona, Spain, and a potential association between specific STs and infection/colonization were identified. [ABSTRACT FROM AUTHOR]
Published: 2022
Full Text: View/download PDF

79. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study

Author: Albasanz-Puig, Adaia, Gudiol, Carlota, Parody, Rocio, Tebe, Cristian, Akova, Murat, Araos, Rafael, Bote, Anna, Brunel, Anne-Sophie, Calik, Sebnem, Drgona, Lubos, Garcia, Estefania, Hemmati, Philipp, Herrera, Fabian, Ibrahim, Karim Yaqub, Isler, Burcu, Kanj, Souha, Kern, Winfried, Maestro de la Calle, Guillermo, Manzur, Adriana, Ivan Marin, Jorge, Marquez-Gomez, Ignacio, Martin-Davila, Pilar, Mikulska, Malgorzata, Montejo, Jose Miguel, Montero, Milagros, Paz Morales, Hugo Manuel, Morales, Isabel, Novo, Andres, Oltolini, Chiara, Peghin, Maddalena, Luis del Pozo, Jose, Puerta-Alcalde, Pedro, Ruiz-Camps, Isabel, Resat Sipahi, Oguz, Tilley, Robert, Yanez, Lucrecia, Ribeiro Gomes, Marisa Zenaide, Carratala, Jordi, Cuervo, Guillermo, Escrihuela-Vidal, Francesc, Tubau, Fe, Rodriguez Arias, Marisol, Merve Ayaz, Caglayan, Munita, Jose, Gasch, Oriol, Capilla, Silvia, Bochud, Pierre-Yves, Manuel, Oriol, Torre-Cisneros, Julian, Tabares, Salvador, Serrano Lopez, Josefina, Maschmeyer, Georg, Torres, Diego, Abdala, Edson, Bittencourt, Driele Peixoto, El Zein, Saeed, Jabbour, Jean-Francois, Bertz, Hartmut, Peyerl-Hoffmann, Gabriele, Lizasoain, Manuel, Maria Aguado, Jose, Clemencia Correa, Lina, Palop, Begona, Fortun, Jesus, Magnasco, Laura, Cespedes, Roberto, Lopez-Soria, Leire, Pablo Horcajada, Juan, Montaguti, Mia Hold, de Cueto, Marina, Rodriguez-Bano, Jesus, Greco, Raffaella, Cichero, Paola, Bassetti, Matteo, Castaldo, Nadia, Sangro del Alcazar, Paloma, Cardozo, Celia, Garcia-Vidal, Carolina, Aguilar-Company, Juan, Larrosa, Nieves, Uyan-Onal, Ayse, Nazli-Zeka, Arzu, Vasconcelos de Freitas, Wania, da Silva Machado, Amanda Aparecida, IRONIC Study Grp, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), European Commission, IRONIC study group, Cuervo, G., Escrihuela-Vidal, F., Arias, M.R., Ayaz, C.M., Munita, J., Gasch, O., Bochud, P.Y., Manuel, O., Torres, D., Zein, S.E., Jabbour, J.F., Bertz, H., Peyerl-Hoffmann, G., Lizasoain, M., Aguado, J.M., Palop, B., Fortún, J., Maschmeyer, G., Magnasco, L., Céspedes, R., López-Soria, L., Horcajada, J.P., Montaguti, M.H., Cueto, M., Rodríguez-Baño, J., Greco, R., Cichero, P., Bassetti, M., Castaldo, N., Del Alcázar, P.S., Cardozo, C., Garcia-Vidal, C., Aguilar-Company, J., Larrosa, N., Uyan-Onal, A., Nazli-Zeka, A., Eylul, D., Turkey, I., Clemencia Correa, L., de Freitas, W.V., da Silva Machado, A.A., Institut Català de la Salut, [Albasanz-Puig A, Gudiol C] Departament de Malalties Infeccioses, Hospital Universitari de Bellvitge, Barcelona, Spain. Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. Universitat de Barcelona, Barcelona, Spain. Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain. [Parody R] Departament d’hematologia, Institut Català d' Oncologia (ICO) Barcelona, Spain. Hospital Duran i Reynals, Barcelona, Spain. . Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. [Tebe C] Servei d’estadística, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. Universitat Rovira i Virgili, Barcelona, Spain. [Akova M] Infectious Diseases Department, Hacettepe University School of Medicine, Ankara, Turkey. [Araos R] Infectious Diseases Department, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana, Universidad del Desarrollo, Santiago de Chile, Chile. [Ruiz-Camps I] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, and Ege Üniversitesi
Subjects: Microbiological Phenomena::Drug Resistance, Microbial [PHENOMENA AND PROCESSES], Research design, infecciones bacterianas y micosis::infecciones bacterianas y micosis::infección::sepsis::bacteriemia [ENFERMEDADES], bacteraemia, Time Factors, modelos logísticos, International Cooperation, humanos, resistencia a medicamentos, Drug Resistance, Bacteremia, Bacteria::bacterias gramnegativas::bacterias aerobias gramnegativas::bacilos y cocos aerobios gramnegativos::Pseudomonadaceae::Pseudomonas::Pseudomonas aeruginosa [ORGANISMOS], bloodstream infection, multidrug-resistant, neutropenia, onco-haematological patients, pseudomonas aeruginosa, estudios multicéntricos como asunto, Bacterièmia, 0302 clinical medicine, Bacteria::Gram-Negative Bacteria::Gram-Negative Aerobic Bacteria::Gram-Negative Aerobic Rods and Cocci::Pseudomonadaceae::Pseudomonas::Pseudomonas aeruginosa [ORGANISMS], Drug Resistance, Multiple, Bacterial, Neoplasms, Clinical endpoint, Onco-haematological patients, Multicenter Studies as Topic, Multidrug-resistant, Microorganismes - Resistència als medicaments, Otros calificadores::Otros calificadores::/inmunología [Otros calificadores], 030212 general & internal medicine, neoplasias, 0303 health sciences, Neutropènia, fenómenos microbiológicos::farmacorresistencia microbiana [FENÓMENOS Y PROCESOS], Incidence (epidemiology), bacteriemia, General Medicine, Bacterial Infections and Mycoses::Bacterial Infections and Mycoses::Infection::Sepsis::Bacteremia [DISEASES], Anti-Bacterial Agents, Malalts de càncer, Observational Studies as Topic, Research Design, Pseudomonas aeruginosa, Ceftolozane, antibacterianos, medicine.drug, medicine.medical_specialty, Tazobactam, Neutropenia, Pseudomones aeruginosa, Bloodstream infection, 03 medical and health sciences, factores de tiempo, Other subheadings::Other subheadings::/immunology [Other subheadings], Internal medicine, Pseudomonas, medicine, Humans, Pseudomonas Infections, Anti-Bacterial Agents/therapeutic use, Bacteremia/drug therapy, Bacteremia/mortality, Cephalosporins/therapeutic use, Logistic Models, Neoplasms/complications, Neutropenia/complications, Pseudomonas Infections/drug therapy, Pseudomonas aeruginosa/isolation & purification, Retrospective Studies, Tazobactam/therapeutic use, Resistència als medicaments, infecciones por Pseudomonas, cefalosporinas, 030306 microbiology, business.industry, estudios retrospectivos, enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos leucocitarios::leucopenia::agranulocitosis::neutropenia [ENFERMEDADES], cooperación internacional, Retrospective cohort study, Cancer patients, medicine.disease, Cephalosporins, Drug resistance, Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia [DISEASES], Bacteraemia, Observational study, business, diseño de la investigación
Abstract: The IRONIC study group: Cuervo, Guillermo; Escrihuela-Vidal, Francesc; Tubau, Fe; Rodriguez Arias, Marisol; Merve Ayaz, Caglayan; Munita, Jose; Gasch, Oriol; Capilla, Silvia; Bochud, Pierre-Yves; Manuel, Oriol; Torre-Cisneros, Julian; Tabares, Salvador; Serrano Lopez, Josefina; Maschmeyer, Georg; Torres, Diego; Abdala, Edson; Bittencourt, Driele Peixoto; El Zein, Saeed; Jabbour, Jean-Francois; Bertz, Hartmut; Peyerl-Hoffmann, Gabriele; Lizasoain, Manuel; Maria Aguado, Jose; Clemencia Correa, Lina; Palop, Begona; Fortun, Jesus; Magnasco, Laura; Cespedes, Roberto; Lopez-Soria, Leire; Pablo Horcajada, Juan; Montaguti, Mia Hold; de Cueto, Marina; Rodriguez-Bano, Jesus; Greco, Raffaella; Cichero, Paola; Bassetti, Matteo; Castaldo, Nadia; Sangro del Alcazar, Paloma; Cardozo, Celia; Garcia-Vidal, Carolina; Aguilar-Company, Juan; Larrosa, Nieves; Uyan-Onal, Ayse; Nazli-Zeka, Arzu; Vasconcelos de Freitas, Wania; da Silva Machado, Amanda Aparecida, [Introduction]: Pseudomonas aeruginosa (PA) has historically been one of the major causes of severe sepsis and death among neutropenic cancer patients. There has been a recent increase of multidrug-resistant PA (MDRPA) isolates that may determine a worse prognosis, particularly in immunosuppressed patients. The aim of this study is to establish the impact of antibiotic resistance on the outcome of neutropenic onco-haematological patients with PA bacteraemia, and to identify the risk factors for MDRPA bacteraemia and mortality., [Methods and analysis]: This is a retrospective, observational, multicentre, international study. All episodes of PA bacteraemia occurring in neutropenic oncohaematological patients followed up at the participating centres from 1 January 2006 to 31 May 2018 will be retrospectively reviewed. The primary end point will be overall case-fatality rate within 30 days of onset of PA bacteraemia. The secondary end points will be to describe the following: the incidence and risk factors for multidrugresistant and extremely drug-resistant PA bacteraemia (by comparing the episodes due to susceptible PA with those produced by MDRPA), the efficacy of ceftolozane/tazobactam, the rates of persistent bacteraemia and bacteraemia relapse and the risk factors for very early (48 hours), early (7 days) and overall (30 days) case-fatality rates., [Ethics and dissemination]: The Clinical Research Ethics Committee of Bellvitge University Hospital approved the protocol of the study at the primary site. To protect personal privacy, identifying information of each patient in the electronic database will be encrypted. The processing of the patients’ personal data collected in the study will comply with the Spanish Data Protection Act of 1998 and with the European Directive on the privacy of data. All data collected, stored and processed will be anonymised. Results will be reported at conferences and in peerreviewed publications., This study was supported by Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001) and co-financed by European Development Regional Fund “A way to achieve Europe”, Operative Programme Intelligent Growth 2014‐2020.
Published: 2019

80. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study

Author: Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), European Commission, Albasanz-Puig, Adaia, Gudiol, Carlota, Parody, Rocío, Tebé, Cristian, Akova, Murat, Araos, Rafael, Bote, Anna, Brunel, Anne-Sophie, Calik, Sebnem, Drgona, Lubos, García, Estefanía, Hemmati, Philipp, Herrera, Fabián, Yaqub Ibrahim, Karim, Isler, Burcu, Kanj, Souha S., Kern, Winfried, Maestro-de la Calle, Guillermo, Manzur, Adriana, Marin, Jorge Iván, Márquez-Gómez, Ignacio, Martín-Dávila, Pilar, Mikulska, Malgorzata, Montejo, Miguel, Montero, Milagros, Paz Morales, Hugo Manuel, Morales, Isabel, Novo, Andrés, Oltolini, Chiara, Peghin, Maddalena, Pozo, José Luis del, Puerta-Alcalde, Pedro, Ruiz-Camps, Isabel, Sipahi, Oguz Resat, Tilley, Robert, Yáñez, Lucrecia, Gomes, Marisa Z. R., Carratalà, Jordi, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), European Commission, Albasanz-Puig, Adaia, Gudiol, Carlota, Parody, Rocío, Tebé, Cristian, Akova, Murat, Araos, Rafael, Bote, Anna, Brunel, Anne-Sophie, Calik, Sebnem, Drgona, Lubos, García, Estefanía, Hemmati, Philipp, Herrera, Fabián, Yaqub Ibrahim, Karim, Isler, Burcu, Kanj, Souha S., Kern, Winfried, Maestro-de la Calle, Guillermo, Manzur, Adriana, Marin, Jorge Iván, Márquez-Gómez, Ignacio, Martín-Dávila, Pilar, Mikulska, Malgorzata, Montejo, Miguel, Montero, Milagros, Paz Morales, Hugo Manuel, Morales, Isabel, Novo, Andrés, Oltolini, Chiara, Peghin, Maddalena, Pozo, José Luis del, Puerta-Alcalde, Pedro, Ruiz-Camps, Isabel, Sipahi, Oguz Resat, Tilley, Robert, Yáñez, Lucrecia, Gomes, Marisa Z. R., and Carratalà, Jordi
Abstract: [Introduction]: Pseudomonas aeruginosa (PA) has historically been one of the major causes of severe sepsis and death among neutropenic cancer patients. There has been a recent increase of multidrug-resistant PA (MDRPA) isolates that may determine a worse prognosis, particularly in immunosuppressed patients. The aim of this study is to establish the impact of antibiotic resistance on the outcome of neutropenic onco-haematological patients with PA bacteraemia, and to identify the risk factors for MDRPA bacteraemia and mortality., [Methods and analysis]: This is a retrospective, observational, multicentre, international study. All episodes of PA bacteraemia occurring in neutropenic oncohaematological patients followed up at the participating centres from 1 January 2006 to 31 May 2018 will be retrospectively reviewed. The primary end point will be overall case-fatality rate within 30 days of onset of PA bacteraemia. The secondary end points will be to describe the following: the incidence and risk factors for multidrugresistant and extremely drug-resistant PA bacteraemia (by comparing the episodes due to susceptible PA with those produced by MDRPA), the efficacy of ceftolozane/tazobactam, the rates of persistent bacteraemia and bacteraemia relapse and the risk factors for very early (48 hours), early (7 days) and overall (30 days) case-fatality rates., [Ethics and dissemination]: The Clinical Research Ethics Committee of Bellvitge University Hospital approved the protocol of the study at the primary site. To protect personal privacy, identifying information of each patient in the electronic database will be encrypted. The processing of the patients’ personal data collected in the study will comply with the Spanish Data Protection Act of 1998 and with the European Directive on the privacy of data. All data collected, stored and processed will be anonymised. Results will be reported at conferences and in peerreviewed publications.
Published: 2019

81. 474 - Vaccination Against Sars-Cov-2 Induces Robust Humoral Immune Response in Patients with Previous Hematologic Stem Cell Transplantation

Author: Roldan, Elisa, Del Carmen Jimenez, Moraima, Villacampa, Guillermo, Fernandez-Naval, Candela, Perez, Ana, Fox, Laura, Orti, Guillermo, Salamero, Olga, Barba, Pere, Campins, Magda, Esperalba, Juliana, Ruiz-Camps, Isabel, Crespo, Marta, Hernández-González, Manuel, Bosch, Francesc, Abrisqueta, Pau, and Valcarcel, David
Published: 2022
Full Text: View/download PDF

82. Chronic Pulmonary Aspergillosis in a Tertiary Care Center in Spain: A Retrospective, Observational Study

Author: Aguilar‐Company, Juan, primary, Martín, María Teresa, additional, Goterris‐Bonet, Lidia, additional, Martinez‐Marti, Alex, additional, Sampol, Júlia, additional, Roldán, Elisa, additional, Almirante, Benito, additional, and Ruiz‐Camps, Isabel, additional
Published: 2019
Full Text: View/download PDF

83. Impact of antibiotic resistance on outcomes of neutropenic cancer patients withPseudomonas aeruginosabacteraemia (IRONIC study): study protocol of a retrospective multicentre international study

Author: Albasanz-Puig, Adaia, primary, Gudiol, Carlota, additional, Parody, Rocío, additional, Tebe, Cristian, additional, Akova, Murat, additional, Araos, Rafael, additional, Bote, Anna, additional, Brunel, Anne-Sophie, additional, Calik, Sebnem, additional, Drgona, Lubos, additional, García, Estefanía, additional, Hemmati, Philipp, additional, Herrera, Fabián, additional, Ibrahim, Karim Yaqub, additional, Isler, Burcu, additional, Kanj, Souha, additional, Kern, Winfried, additional, Maestro de la Calle, Guillermo, additional, Manzur, Adriana, additional, Marin, Jorge Iván, additional, Márquez-Gómez, Ignacio, additional, Martín-Dávila, Pilar, additional, Mikulska, Malgorzata, additional, Montejo, José Miguel, additional, Montero, Milagros, additional, Morales, Hugo Manuel Paz, additional, Morales, Isabel, additional, Novo, Andrés, additional, Oltolini, Chiara, additional, Peghin, Maddalena, additional, del Pozo, Jose Luis, additional, Puerta-Alcalde, Pedro, additional, Ruiz-Camps, Isabel, additional, Sipahi, Oguz Resat, additional, Tilley, Robert, additional, Yáñez, Lucrecia, additional, Gomes, Marisa Zenaide Ribeiro, additional, and Carratalà, Jordi, additional
Published: 2019
Full Text: View/download PDF

84. Assessment of and future perspectives on standards of CARE in invasive fungal disease

Author: Muñoz, Patricia, primary, Ruiz-Camps, Isabel, additional, and Richardson, Malcolm D, additional
Published: 2019
Full Text: View/download PDF

85. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry

Author: Pinato, David J., Patel, Meera, Scotti, Lorenza, Colomba, Emeline, Dolly, Saoirse, Loizidou, Angela, Chester, John, Mukherjee, Uma, Zambelli, Alberto, Dalla Pria, Alessia, Aguilar-Company, Juan, Bower, Mark, Salazar, Ramon, Bertuzzi, Alexia, Brunet, Joan, Lambertini, Matteo, Tagliamento, Marco, Pous, Anna, Sita-Lumsden, Ailsa, Srikandarajah, Krishnie, Colomba, Johann, Pommeret, Fanny, Seguí, Elia, Generali, Daniele, Grisanti, Salvatore, Pedrazzoli, Paolo, Rizzo, Gianpiero, Libertini, Michela, Moss, Charlotte, Evans, Joanne S., Russell, Beth, Harbeck, Nadia, Vincenzi, Bruno, Biello, Federica, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Rossi, Sabrina, Carmona-García, M. Carmen, Tondini, Carlo, Fox, Laura, Baggi, Alice, Fotia, Vittoria, Parisi, Alessandro, Porzio, Giampero, Queirolo, Paola, Cruz, Claudia Andrea, Saoudi-Gonzalez, Nadia, Felip, Eudald, Roqué Lloveras, Ariadna, Newsom-Davis, Thomas, Sharkey, Rachel, Roldán, Elisa, Reyes, Roxana, Zoratto, Federica, Earnshaw, Irina, Ferrante, Daniela, Marco-Hernández, Javier, Ruiz-Camps, Isabel, Gaidano, Gianluca, Patriarca, Andrea, Bruna, Riccardo, Sureda, Anna, Martinez-Vila, Clara, Sanchez de Torre, Ana, Berardi, Rossana, Giusti, Raffaele, Mazzoni, Francesca, Guida, Annalisa, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Krengli, Marco, Santoro, Armando, Prat, Aleix, Tabernero, Josep, Van Hemelrijck, Mieke, Diamantis, Nikolaos, Gennari, Alessandra, and Cortellini, Alessio
Abstract: IMPORTANCE: Whether the severity and mortality of COVID-19 in patients with cancer have improved in terms of disease management and capacity is yet to be defined. OBJECTIVE: To test whether severity and mortality from COVID-19 among patients with cancer have improved during the course of the pandemic. DESIGN, SETTING, AND PARTICIPANTS: OnCovid is a European registry that collects data on consecutive patients with solid or hematologic cancer and COVID-19. This multicenter case series study included real-world data from 35 institutions across 6 countries (UK, Italy, Spain, France, Belgium, and Germany). This update included patients diagnosed between February 27, 2020, and February, 14, 2021. Inclusion criteria were confirmed diagnosis of SARS-CoV-2 infection and a history of solid or hematologic cancer. EXPOSURES: SARS-CoV-2 infection. MAIN OUTCOMES AND MEASURES: Deaths were differentiated at 14 days and 3 months as the 2 landmark end points. Patient characteristics and outcomes were compared by stratifying patients across 5 phases (February to March 2020, April to June 2020, July to September 2020, October to December 2020, and January to February 2021) and across 2 major outbreaks (February to June 2020 and July 2020 to February 2021). RESULTS: At data cutoff, 2795 consecutive patients were included, with 2634 patients eligible for analysis (median [IQR] age, 68 [18-77] years ; 52.8% men). Eligible patients demonstrated significant time-dependent improvement in 14-day case-fatality rate (CFR) with estimates of 29.8% (95% CI, 0.26-0.33) for February to March 2020; 20.3% (95% CI, 0.17-0.23) for April to June 2020; 12.5% (95% CI, 0.06-22.90) for July to September 2020; 17.2% (95% CI, 0.15-0.21) for October to December 2020; and 14.5% (95% CI, 0.09-0.21) for January to February 2021 (all P < .001) across the predefined phases. Compared with the second major outbreak, patients diagnosed in the first outbreak were more likely to be 65 years or older (974 of 1626 [60.3%] vs 564 of 1008 [56.1%]; P = .03), have at least 2 comorbidities (793 of 1626 [48.8%] vs 427 of 1008 [42.4%]; P = .001), and have advanced tumors (708 of 1626 [46.4%] vs 536 of 1008 [56.1%]; P < .001). Complications of COVID-19 were more likely to be seen (738 of 1626 [45.4%] vs 342 of 1008 [33.9%]; P < .001) and require hospitalization (969 of 1626 [59.8%] vs 418 of 1008 [42.1%]; P < .001) and anti–COVID-19 therapy (1004 of 1626 [61.7%] vs 501 of 1008 [49.7%]; P < .001) during the first major outbreak. The 14-day CFRs for the first and second major outbreaks were 25.6% (95% CI, 0.23-0.28) vs 16.2% (95% CI, 0.13-0.19; P < .001), respectively. After adjusting for country, sex, age, comorbidities, tumor stage and status, anti–COVID-19 and anticancer therapy, and COVID-19 complications, patients diagnosed in the first outbreak had an increased risk of death at 14 days (hazard ratio [HR], 1.85; 95% CI, 1.47-2.32) and 3 months (HR, 1.28; 95% CI, 1.08-1.51) compared with those diagnosed in the second outbreak. CONCLUSIONS AND RELEVANCE: The findings of this registry-based study suggest that mortality in patients with cancer diagnosed with COVID-19 has improved in Europe; this improvement may be associated with earlier diagnosis, improved management, and dynamic changes in community transmission over time.
Published: 2022
Full Text: View/download PDF

86. Short‐course antibiotic treatment for Gram‐negative bloodstream infection in neutropenic cancer patients: Less is more.

Author: Ruiz‐Camps, Isabel and Albasanz‐Puig, Adaia
Subjects: *GRAM-negative bacteria, *CANCER patients, *CATHETER-related infections, *BONE marrow transplantation, *ANTIBIOTICS, *HEMATOPOIETIC stem cell transplantation, *INTRA-abdominal infections
Abstract: Bloodstream infections (BSI) remain one of the leading complications in immunosuppressed patients with hematologic malignancies (HM) and hematopoietic stem cell transplants (HSCTs). Short-course antibiotic treatment for Gram-negative bloodstream infection in neutropenic cancer patients: Less is more Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial. [Extracted from the article]
Published: 2023
Full Text: View/download PDF

87. Recomendaciones sobre la prevención de la infección fúngica invasora por hongos filamentosos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC)

Author: Ruiz-Camps, Isabel, Aguado, Jose María, Almirante, Benito, Bouza, Emilio, Ferrer Barbera, Carmen, Len, Oscar, López-Cerero, Lorena, Rodríguez-Tudela, Juan Luis, Ruiz, Miguel, Solé, Amparo, Vallejo, Carlos, Vázquez, Lourdes, Zaragoza, Rafael, and Cuenca-Estrella, Manuel
Published: 2010
Full Text: View/download PDF

88. Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients

Author: Vazquez, L, Salavert, M, Gayoso, J, Lizasoain, M, Ruiz Camps, Isabel, Di Benedetto, N, and Study Grp Risk Factors IFI Using
Subjects: stratification, Delphi method, risk factors, invasive fungal infection
Abstract: Introduction. Mortality caused by invasive fungal infections due to filamentous fungi (IFI-FF) is high. Predisposing factors to IFI-FF are multiple and should be stratified. The objective of this study was to identify key risk factors for IFI-FF in onco-haematological patients in different clinical settings. Methods. Prospective national Delphi study. Risk factors for IFI-FF in patients with onco-haematological diseases were identified by a systematic review of the literature. An anonymous survey was sent by e-mail to a panel of experts. A key risk factor was defined when at least 70% of the surveyed participants assigned a "maximal" or "high" risk. Results. In allogenic stem cell transplantation, 18 of the 42 risk factors analyzed were classified as key risk factors, including neutropenia, previous IFI-FF, grade III/IV acute or extensive chronic graft-versus-host disease (GVHD), umbilical cord blood transplantation, HLA mismatching transplantation, graft failure, absence of HEPA filters, absence of laminar air flow, diagnosis of acute myeloid leukaemia, haploidentical transplantation, anti-TNF-alpha drugs, alemtuzumab, anti-thymocyte globulin, immunosuppressive prophylaxis for GVHD, lymphocytopenia, cytomegalovirus infection, and proximity to construction areas. In acute leukaemia/myelodysplastic syndrome (AL/MDS), 7 of 25 risk factors were defined as key risk factors, including neutropenia, consolidation therapy without response, induction therapy, antifungal prophylaxis with azoles, proximity to construction areas, and absence of HEPA filters. In lymphoma/multiple myeloma (MM), the five key risk factors among 21 analyzed were use of steroids, neutropenia, progressive disease, anti-CD52 therapies, and proximity to construction areas. Conclusions. The Delphi method was useful for the classification and stratification of risk factors for IFI-FF in patients with onco-haematological diseases. Identifying key risk factors will contribute to a better management of IFI-FF in this group of patients at high or changing risk.
Published: 2017

89. Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR)

Author: Gudiol, Carlota, Royo-Cebrecos, Cristina, Tebé, Cristian, Abdala, Edson, Akova, Murat, Álvarez-Marín, Rocío, Maestro-de la Calle, Guillermo, Cano, Ángela, Cervera, Carlos, Clemente, Wanessa T., Martín-Dávila, Pilar, Freifeld, Alison, Gómez, Lucía, Gottlieb, Thomas, Gurguí, Mercè, Herrera, Fabián, Manzur, Adriana, Maschmeyer, Georg, Meije, Yolanda, Montejo, Miguel, Peghin, Maddalena, Rodríguez-Baño, Jesús, Ruiz-Camps, Isabel, Sukiennik, Teresa C., Carratalà, Jordi, BICAR study group., [Gudiol,C, Royo-Cebrecos,C, Carratalà,J] Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. [Gudiol,C] Duran i Reynals Hospital, ICO, L'Hospitalet de Llobregat, Barcelona, Spain. [Gudiol,C, Cano,A, Meije,Y, Montejo,M, Rodríguez-Baño,J, Ruiz-Camps,I, Carratalà,J] REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain. [Tebe,C] Statistics Advisory Service, Institute of Biomedical Research of Bellvitge, Rovira i Virgili University, L'Hospitalet de Llobregat, Barcelona, Spain. [Abdala,E] Faculty of Medicine, Instituto do Câncer do Estado de São Paulo, University of São Paulo, Sao Paulo, Brazil. [Akova,M] Hacettepe University School of Medicine, Ankara, Turkey. [Álvarez,R] Infectious Diseases Research Group, Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain. [Maestro-de la Calle,G] Infectious Diseases Unit, Instituto de Investigación Hospital '12 de Octubre' (i+12), '12 de Octubre' University Hospital, School of Medicine, Universidad Complutense, Madrid, Spain. [Cano,A] Reina Sofía University Hospital-IMIBIC-UCO, Córdoba, Spain. [Cervera,C] University Hospital of Alberta, Edmonton, Alberta, Canada. [Clemente,WT] Infectious Disease Consultant, Digestive Transplant Service, Hospital das Clínicas, Universidade Federal Minas Gerais, Brazil. [Martín-Dávila,P] Infectious Diseases Department, Ramon y Cajal Hospital, Madrid, Spain. [Freifeld,A] Infectious Diseases Section, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. [Gómez,L] Department of Internal Medicine, University Hospital Mútua de Terrassa, Barcelona, Spain. [Gottlieb,T] Department of Microbiology & Infectious Diseases, Concord Hospital, Concord, New South Wales, Australia. [Gurguí,M] Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau and Instituto de Investigación Biomédica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. [Herrera,F] Infectious Diseases Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina. [Manzur,A] Infectious Diseases, Hospital Rawson, San Juan, Argentina. [Maschmeyer,G] Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Academic Teaching Hospital of Charité University Medical School, Berlin, Germany. [Meije,Y] Infectious Disease Unit, Internal Medicine Department, Barcelona Hospital, SCIAS, Barcelona, Spain. [Montejo,M] Infectious Diseases Unit, Cruces University Hospital, Bilbao, Spain. [Peghin,M] Infectious Diseases Division, Santa Maria Misericordia University Hospital, Udine, Italy. [Rodríguez-Baño,J] Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, University Hospitals Virgen Macarena and Virgen del Rocío-IBiS, Department of Medicine, University of Seville, Seville, Spain. [Ruiz-Camps,I] Infectious Diseases Department, Vall d'Hebrón University Hospital, Barcelona, Spain. [Sukiennik,TC] Hospital Santa Casa de Misericórdia de Porto Alegre, Brazil., This study was supported by Ministerio de Economía y Competitividad, Instituto de Salud Carlos III—co-financed by European Development Regional Fund ‘A way to achieve Europe’ ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015)., Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, and Red Española de Investigación en Patología Infecciosa
Subjects: Humanities::Humanities::Ethics::Ethics Committees::Ethics Committees, Research [Medical Subject Headings], Male, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings], Bacteremia, Comités de ética en investigación, Carbapenémicos, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], haematologic stem cell transplant, polycyclic compounds, Protocol, beta-lactam/beta-lactamase inhibitors, Diseases::Bacterial Infections and Mycoses::Infection::Sepsis [Medical Subject Headings], Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Amidohydrolases::beta-Lactamases [Medical Subject Headings], Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Bacteremia [Medical Subject Headings], Enterobacteriaceae Infections, Hematopoietic Stem Cell Transplantation, Haematologic stem cell transplant, Middle Aged, Anti-Bacterial Agents, Infectious Diseases, Organisms [Medical Subject Headings], Beta-lactam/beta-lactamase inhibitors, Hematologic Neoplasms, Organisms::Bacteria::Gram-Negative Bacteria [Medical Subject Headings], Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia [Medical Subject Headings], Drug Therapy, Combination, Female, beta-Lactamase Inhibitors, Chemicals and Drugs::Organic Chemicals::Amides::Lactams::beta-Lactams::Carbapenems [Medical Subject Headings], Trasplante de células madre hematopoyéticas, Adult, Neutropenia, Adolescent, beta-Lactams, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Hematopoietic Stem Cell Mobilization [Medical Subject Headings], Health Care::Health Care Facilities, Manpower, and Services::Health Facilities::Hospital Units::Intensive Care Units [Medical Subject Headings], Chemicals and Drugs::Organic Chemicals::Amides::Lactams::beta-Lactams [Medical Subject Headings], Humans, Bacterias gramnegativas, Aged, Retrospective Studies, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses, ESBLs, Superinfection, bacteria, Bacteraemia, Diseases::Bacterial Infections and Mycoses::Infection::Opportunistic Infections::Superinfection [Medical Subject Headings], human activities
Abstract: [Introduction] Bloodstream infection (BSI) due to extended-spectrum β-lactamase-producing Gram-negative bacilli (ESBL-GNB) is increasing at an alarming pace worldwide. Although β-lactam/β-lactamase inhibitor (BLBLI) combinations have been suggested as an alternative to carbapenems for the treatment of BSI due to these resistant organisms in the general population, their usefulness for the treatment of BSI due to ESBL-GNB in haematological patients with neutropaenia is yet to be elucidated. The aim of the BICAR study is to compare the efficacy of BLBLI combinations with that of carbapenems for the treatment of BSI due to an ESBL-GNB in this population., [Methods and analysis] A multinational, multicentre, observational retrospective study. Episodes of BSI due to ESBL-GNB occurring in haematological patients and haematopoietic stem cell transplant recipients with neutropaenia from 1 January 2006 to 31 March 2015 will be analysed. The primary end point will be case-fatality rate within 30 days of onset of BSI. The secondary end points will be 7-day and 14-day case-fatality rates, microbiological failure, colonisation/infection by resistant bacteria, superinfection, intensive care unit admission and development of adverse events., [Sample size] The number of expected episodes of BSI due to ESBL-GNB in the participant centres will be 260 with a ratio of control to experimental participants of 2., [Ethics and dissemination] The protocol of the study was approved at the first site by the Research Ethics Committee (REC) of Hospital Universitari de Bellvitge. Approval will be also sought from all relevant RECs. Any formal presentation or publication of data from this study will be considered as a joint publication by the participating investigators and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE). The study has been endorsed by the European Study Group for Bloodstream Infection and Sepsis (ESGBIS) and the European Study Group for Infections in Compromised Hosts (ESGICH)., This study was supported by Ministerio de Economía y Competitividad, Instituto de Salud Carlos III—co-financed by European Development Regional Fund ‘A way to achieve Europe’ ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015).
Published: 2017

90. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain

Author: Ruiz Camps, Isabel
Subjects: body regions, genetic structures, 615 - Farmacologia. Terapèutica. Toxicologia. Radiologia, Hospital Universitari Vall d’Hebron, sense organs, Economia, Farmacologia i farmàcia
Abstract: OBJECTIVE: According to a recent randomized, double-blind clinical trial comparing the combination of voriconazole and anidulafungin (VOR+ANI) with VOR monotherapy for invasive aspergillosis (IA) in patients with hematologic disease or with hematopoietic stem cell transplant, mortality was lower after 6 weeks with VOR+ANI than with VOR monotherapy in a post hoc analysis of patients with galactomannan-based IA. The objective of this study was to compare the cost-effectiveness of VOR+ANI with VOR, from the perspective of hospitals in the Spanish National Health System. METHODS: An economic model with deterministic and probabilistic analyses was used to determine costs per life-year gained (LYG) for VOR+ANI versus VOR in patients with galactomannan-based IA. Mortality, adverse event rates, and life expectancy were obtained from clinical trial data. The costs (in 2015 euros [euro]) of the drugs and the adverse event-related costs were obtained from Spanish sources. A Tornado plot and a Monte Carlo simulation (1,000 iterations) were used to assess uncertainty of all model variables. RESULTS: According to the deterministic analysis, for each patient treated with VOR+ANI compared with VOR monotherapy, there would be a total of 0.348 LYG (2.529 vs 2.181 years, respectively) at an incremental cost of euro5,493 (euro17,902 vs euro12,409, respectively). Consequently, the additional cost per LYG with VOR+ANI compared with VOR would be euro15,785. Deterministic sensitivity analyses confirmed the robustness of these findings. In the probabilistic analysis, the cost per LYG with VOR+ANI was euro15,774 (95% confidence interval: euro15,763-16,692). The probability of VOR+ANI being cost-effective compared with VOR was estimated at 82.5% and 91.9%, based on local cost-effectiveness thresholds of euro30,000 and euro45,000, respectively. CONCLUSION: According to the present economic study, combination therapy with VOR+ANI is cost-effective as primary therapy of IA in galactomannan-positive patients in Spain who have hematologic disease or hematopoietic stem cell transplant, compared with VOR monotherapy.
Published: 2016

91. Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC).

Author: López-Sánchez, Cristina, Valcárcel, David, Gómez, Valle, López-Jiménez, Javier, Serrano, David, Rubio, Vicente, Solano, Carlos, Vázquez, Lourdes, and Ruiz-Camps, Isabel
Subjects: MYCOSES, ANTIFUNGAL agents, PREVENTIVE medicine, STEM cell transplantation, GRAFT versus host disease, DRUG interactions
Abstract: Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Published: 2020
Full Text: View/download PDF

92. Early Oral Switch to Linezolid for Low-risk Patients With Staphylococcus aureus Bloodstream Infections: A Propensity-matched Cohort Study

Author: Willekens, Rein, primary, Puig-Asensio, Mireia, additional, Ruiz-Camps, Isabel, additional, Larrosa, Maria N, additional, González-López, Juan J, additional, Rodríguez-Pardo, Dolors, additional, Fernández-Hidalgo, Nuria, additional, Pigrau, Carles, additional, and Almirante, Benito, additional
Published: 2018
Full Text: View/download PDF

93. Effectiveness of a Double-Carbapenem Regimen in a KPC-Producing Klebsiella pneumoniae Infection in an Immunocompromised Patient

Author: Piedra-Carrasco, Nuria, primary, Miguel, Lucia, additional, Fàbrega, Anna, additional, Viñado, Belén, additional, Campany, David, additional, Mir, Alba, additional, Fox, María Laura, additional, Almirante, Benito, additional, Larrosa, Nieves, additional, Ruiz-Camps, Isabel, additional, and González-López, Juan José, additional
Published: 2018
Full Text: View/download PDF

94. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients:Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group

Author: Averbuch, Diana, Tridello, Gloria, Hoek, Jennifer, Mikulska, Malgorzata, Akan, Hamdi, Yanez San Segundo, Lucrecia, Pabst, Thomas, Özçelik, Tülay, Klyasova, Galina, Donnini, Irene, Wu, Depei, Gülbas, Zafer, Zuckerman, Tsila, Botelho de Sousa, Aida, Beguin, Yves, Xhaard, Aliénor, Bachy, Emmanuel, Ljungman, Per, de la Camara, Rafael, Rascon, Jelena, Ruiz Camps, Isabel, Vitek, Antonin, Patriarca, Francesca, Cudillo, Laura, Vrhovac, Radovan, Shaw, Peter J, Wolfs, Tom, O'Brien, Tracey, Avni, Batia, Silling, Gerda, Al Sabty, Firas, Graphakos, Stelios, Sankelo, Marja, Sengeloev, Henrik, Pillai, Srinivas, Matthes, Susanne, Melanthiou, Frederiki, Iacobelli, Simona, Styczynski, Jan, Engelhard, Dan, Cesaro, Simone, Averbuch, Diana, Tridello, Gloria, Hoek, Jennifer, Mikulska, Malgorzata, Akan, Hamdi, Yanez San Segundo, Lucrecia, Pabst, Thomas, Özçelik, Tülay, Klyasova, Galina, Donnini, Irene, Wu, Depei, Gülbas, Zafer, Zuckerman, Tsila, Botelho de Sousa, Aida, Beguin, Yves, Xhaard, Aliénor, Bachy, Emmanuel, Ljungman, Per, de la Camara, Rafael, Rascon, Jelena, Ruiz Camps, Isabel, Vitek, Antonin, Patriarca, Francesca, Cudillo, Laura, Vrhovac, Radovan, Shaw, Peter J, Wolfs, Tom, O'Brien, Tracey, Avni, Batia, Silling, Gerda, Al Sabty, Firas, Graphakos, Stelios, Sankelo, Marja, Sengeloev, Henrik, Pillai, Srinivas, Matthes, Susanne, Melanthiou, Frederiki, Iacobelli, Simona, Styczynski, Jan, Engelhard, Dan, and Cesaro, Simone
Abstract: Background: This intercontinental study aimed to study gram-negative rod (GNR) resistance in hematopoietic stem cell transplantation (HSCT).Methods: GNR bacteremias occurring during 6 months post-HSCT (February 2014-May 2015) were prospectively collected, and analyzed for rates and risk factors for resistance to fluoroquinolones, noncarbapenem anti-Pseudomonas β-lactams (noncarbapenems), carbapenems, and multidrug resistance.Results: Sixty-five HSCT centers from 25 countries in Europe, Australia, and Asia reported data on 655 GNR episodes and 704 pathogens in 591 patients (Enterobacteriaceae, 73%; nonfermentative rods, 24%; and 3% others). Half of GNRs were fluoroquinolone and noncarbapenem resistant; 18.5% carbapenem resistant; 35.2% multidrug resistant. The total resistance rates were higher in allogeneic HSCT (allo-HSCT) vs autologous HSCT (auto-HSCT) patients (P < .001) but similar in community-acquired infections. Noncarbapenem resistance and multidrug resistance were higher in auto-HSCT patients in centers providing vs not providing fluoroquinolone prophylaxis (P < .01). Resistance rates were higher in southeast vs northwest Europe and similar in children and adults, excluding higher fluoroquinolone- and β-lactam/β-lactamase inhibitor resistance rates in allo-HSCT adults. Non-Klebsiella Enterobacteriaceae were rarely carbapenem resistant. Multivariable analysis revealed resistance risk factors in allo-HSCT patients: fluoroquinolone resistance: adult, prolonged neutropenia, breakthrough on fluoroquinolones; noncarbapenem resistance: hospital-acquired infection, breakthrough on noncarbapenems or other antibiotics (excluding fluoroquinolones, noncarbapenems, carbapenems), donor type; carbapenem resistance: breakthrough on carbapenem, longer hospitalization, intensive care unit, previous other antibiotic therapy; multidrug resistance: longer hospitalization, breakthrough on β-lactam/β-lactamase inhibitors, and carbapenems. Inappropriate empi
Published: 2017

95. Manejo de la infección y la neutropenia febril en el paciente con cáncer sólido

Author: Aguado, José María, Cruz, Juan Jesús, Virizuela, Juan Antonio, Aguilar Guisado, Manuela, Carmona, Alberto, Cassinello, Javier, Gudiol, Carlota, Jiménez-Fonseca, Paula, Lizasoain, Manuel, Marco, Francesc, Ruiz-Camps, Isabel, Ruiz, Maribel, Salavert, Miguel, Vicente, David, Carratalà, Jordi, Aguado, José María, Cruz, Juan Jesús, Virizuela, Juan Antonio, Aguilar Guisado, Manuela, Carmona, Alberto, Cassinello, Javier, Gudiol, Carlota, Jiménez-Fonseca, Paula, Lizasoain, Manuel, Marco, Francesc, Ruiz-Camps, Isabel, Ruiz, Maribel, Salavert, Miguel, Vicente, David, and Carratalà, Jordi
Abstract: [ES] Un grupo de expertos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y de la Sociedad Española de Oncología Médica (SEOM) han revisado en este documento los principales aspectos que deben considerarse en la evaluación de los pacientes con cáncer sólido y complicaciones infecciosas. Para ello se han establecido unas recomendaciones sobre la profilaxis de las infecciones más prevalentes en estos pacientes, el uso de vacunas, las medidas de control de la infección por catéteres vasculares y la prevención de la infección ante determinadas maniobras quirúrgicas. A continuación, se han revisado los criterios de manejo de la neutropenia febril y del uso de factores estimulantes de colonias, para terminar dando una serie de pautas sobre el tratamiento del paciente oncológico con infección grave. El documento se completa con una serie de medidas para el control de la infección hospitalaria., [EN] A group of experts from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Medical Oncology (SEOM) have reviewed in this paper the main aspects to be considered in the evaluation of patients with solid cancer and infectious diseases. They have established a series of recommendations on the prevention of the most prevalent infections in these patients, the use of vaccines, the control measures of vascular catheter infection and prevention of infections before certain surgical procedures. Also the criteria for management of febrile neutropenia and the use of colony-stimulating factors were revised. Finally they provide a series of recommendations for the treatment of cancer patients with severe infection. The document is completed with a series of measures for the control of hospital infection.
Published: 2017

96. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia

Author: Gudiol, Carlota, primary, Royo-Cebrecos, Cristina, additional, Abdala, Edson, additional, Akova, Murat, additional, Álvarez, Rocío, additional, Maestro-de la Calle, Guillermo, additional, Cano, Angela, additional, Cervera, Carlos, additional, Clemente, Wanessa T., additional, Martín-Dávila, Pilar, additional, Freifeld, Alison, additional, Gómez, Lucía, additional, Gottlieb, Thomas, additional, Gurguí, Mercè, additional, Herrera, Fabián, additional, Manzur, Adriana, additional, Maschmeyer, Georg, additional, Meije, Yolanda, additional, Montejo, Miguel, additional, Peghin, Maddalena, additional, Rodríguez-Baño, Jesús, additional, Ruiz-Camps, Isabel, additional, Sukiennik, Teresa C., additional, Tebe, Cristian, additional, and Carratalà, Jordi, additional
Published: 2017
Full Text: View/download PDF

97. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group

Author: Averbuch, Diana, primary, Tridello, Gloria, additional, Hoek, Jennifer, additional, Mikulska, Malgorzata, additional, Akan, Hamdi, additional, Yaňez San Segundo, Lucrecia, additional, Pabst, Thomas, additional, Özçelik, Tülay, additional, Klyasova, Galina, additional, Donnini, Irene, additional, Wu, Depei, additional, Gülbas, Zafer, additional, Zuckerman, Tsila, additional, Botelho de Sousa, Aida, additional, Beguin, Yves, additional, Xhaard, Aliénor, additional, Bachy, Emmanuel, additional, Ljungman, Per, additional, de la Camara, Rafael, additional, Rascon, Jelena, additional, Ruiz Camps, Isabel, additional, Vitek, Antonin, additional, Patriarca, Francesca, additional, Cudillo, Laura, additional, Vrhovac, Radovan, additional, Shaw, Peter J, additional, Wolfs, Tom, additional, O’Brien, Tracey, additional, Avni, Batia, additional, Silling, Gerda, additional, Al Sabty, Firas, additional, Graphakos, Stelios, additional, Sankelo, Marja, additional, Sengeloev, Henrik, additional, Pillai, Srinivas, additional, Matthes, Susanne, additional, Melanthiou, Frederiki, additional, Iacobelli, Simona, additional, Styczynski, Jan, additional, Engelhard, Dan, additional, and Cesaro, Simone, additional
Published: 2017
Full Text: View/download PDF

98. Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

Author: Castón, Juan José, primary, De la Torre, Álvaro, additional, Ruiz-Camps, Isabel, additional, Sorlí, María Luisa, additional, Torres, Vicente, additional, and Torre-Cisneros, Julián, additional
Published: 2017
Full Text: View/download PDF

99. Imported Disease Screening Prior to Chemotherapy and Bone Marrow Transplantation for Oncohematological Malignancies

Author: Sánchez-Montalvá, Adrián, primary, Ruiz-Camps, Isabel, additional, Barba, Pere, additional, Valcárcel, David, additional, Sulleiro, Elena, additional, Sanz-García, Enrique, additional, Molina, Israel, additional, and Salvador, Fernando, additional
Published: 2016
Full Text: View/download PDF

100. Early Oral Switch to Linezolid for Low-risk Patients With Staphylococcus aureus Bloodstream Infections: A Propensity-matched Cohort Study.

Author: Willekens, Rein, Puig-Asensio, Mireia, Ruiz-Camps, Isabel, Larrosa, Maria N, González-López, Juan J, Rodríguez-Pardo, Dolors, Fernández-Hidalgo, Nuria, Pigrau, Carles, and Almirante, Benito
Subjects: ACADEMIC medical centers, ALGORITHMS, BACTEREMIA, BLOODBORNE infections, TUBERCULOSIS of the bones, GENERIC drug substitution, LENGTH of stay in hospitals, HOSPITAL admission & discharge, INTRAVENOUS therapy, JOINT tuberculosis, LONGITUDINAL method, ORAL drug administration, SKIN diseases, STAPHYLOCOCCAL diseases, TREATMENT effectiveness, CATHETER-related infections, DISEASE risk factors, LINEZOLID, THERAPEUTICS
Abstract: Background Oral switch to linezolid is a promising alternative to standard parenteral therapy (SPT) in Staphylococcus aureus bacteremia (SAB). Methods We conducted a prospective cohort study of all adult cases of SAB between 2013 and 2017 in a Spanish university hospital. We compared the efﬁcacy, safety, and length of hospital stay of patients receiving SPT and those where SPT was switched to oral linezolid between days 3 and 9 of treatment until completion. We excluded complicated SAB and osteoarticular infections. A k-nearest neighbor algorithm was used for propensity score matching with a 2:1 ratio. Results After propensity score matching, we included 45 patients from the linezolid group and 90 patients from the SPT group. Leading SAB sources were catheter related (49.6%), unknown origin (20.0%), and skin and soft tissue (17.0%). We observed no difference in 90-day relapse between the linezolid group and the SPT group (2.2% vs 4.4% respectively; P =.87). No statistically significant difference was observed in 30-day all-cause mortality between the linezolid group and the SPT group (2.2% vs 13.3%; P =.08). The median length of hospital stay after onset was 8 days in the linezolid group and 19 days in the SPT group (P <.01). No drug-related events leading to discontinuation were noted in the linezolid group. Conclusions Treatment of SAB in selected low-risk patients with an oral switch to linezolid between days 3 and 9 of treatment until completion yielded similar clinical outcomes as SPT, allowing earlier discharge from the hospital. [ABSTRACT FROM AUTHOR]
Published: 2019
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

307 results on '"Ruiz-Camps, Isabel"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources